This is not the most recent version of the article. View current version (13 APR 2015)

Intervention Protocol

You have free access to this content

Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia

  1. Adegoke Oloruntoba Adelufosi1,*,
  2. Olukayode Abayomi2,
  3. Tunde Massey-Ferguson Ojo3

Editorial Group: Cochrane Schizophrenia Group

Published Online: 30 APR 2013

DOI: 10.1002/14651858.CD010501

How to Cite

Adelufosi AO, Abayomi O, Ojo TMF. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD010501. DOI: 10.1002/14651858.CD010501.

Author Information

  1. 1

    LAUTECH Teaching Hospital, Department of Psychiatry, Ogbomoso, Oyo State, Nigeria

  2. 2

    Ladoke Akintola University Teaching Hospital, Psychiatry, Ogbomoso, Oyo, Nigeria

  3. 3

    Neuropsychiatric Hospital, Clinicial Sciences (Resident Doctors Office), Ogun State, Nigeria

*Adegoke Oloruntoba Adelufosi, Department of Psychiatry, LAUTECH Teaching Hospital, Ogbomoso, Oyo State, Nigeria.

Publication History

  1. Publication Status: New
  2. Published Online: 30 APR 2013


This is not the most recent version of the article. View current version (13 APR 2015)


Additional references

Adler 1998
Altman 1996
Barnes 1993
  • Barnes TRE, Edwards JG. The side-effects of antipsychotic drugs. In: Barnes TRE editor(s). Antipsychotic Drugs and their Side-effects. CNS and Neuromuscular effects. Vol. I, London: Harcourt Brace & Company, 1993.
Bassitt 1998
Bland 1997
Boissel 1999
  • Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
Browne 1996
Caroff 2001
Casey 1995
  • Casey DE. Neuroleptic-induced extrapyramidal syndromes and tardive dyskinesia. In: Hirsch S, Weinberger DR editor(s). Schizophrenia. Oxford: Blackwell, 1995:546–65.
Chakos 1996
  • Chakos MH, Alvir JMJ, Woerner MG, Koreen A, Geisler S, Mayerhoff D, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Archives of General Psychiatry 1996;53:313–9.
Corell 2008
Deeks 2000
  • Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
Divine 1992
Donner 2002
Egger 1997
  • Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
Elbourne 2002
  • Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
Fay-McCarthy 1997
  • Fay-McCarthy M, Kendrick KA, Rosse RB, Schwartz BL, Peace T, Wyatt RJ, et al. The effect of nifedipine on tardive dyskinesia: a double blind study in eighteen patients. Schizophrenia Research 1997;24(1-2):271.
Fenton 2000
Furukawa 2006
  • Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
Gulliford 1999
  • Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: Data from the health survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from
Hutton 2009
Kane 1986
Kay 1986
  • Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
Lerner 2001
  • Lerner V, Miodownik C, Kaptsan A, Cohen H, Matar M, Loewenthal U, et al. Vitamin B6 in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. American Journal of Psychiatry 2001;158:1511-4.
Lerner 2007
  • Lerner V, Miodownik C, Kaptsan A, Bersudsky Y, Libov I, Sela BA, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. Journal of Clinical  Psychiatry 2007;68:1648–54.
Leucht 2005
Leucht 2005a
  • Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
Leucht 2007
  • Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
Marshall 2000
  • Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
McGrath 2001
  • McGrath J, Soares-Weiser K. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD000209]
Miodownik 2008
  • Miodownik C, Meoded A, Libov I, Bersudsky Y, Sela B, Lerner V. Pyridoxal plasma level in schizophrenic and schizoaffective patients with and without tardive dyskinesia. Clinical Neuropharmacology 2008;31:197-203.
Nasrallah 2006
  • Nasrallah HA. Focus on lower risk of tardive dyskinesia with atypical antipsychotics. Annals of Clinical Psychiatry 2006;18(1):57-62.
Nelson 2003
Niehaus 2008
  • Niehaus DJH, Du Plessis SA,  Koen L, Lategan BH, Steyn J, Oosthuizen PP, et al. Predictors of abnormal involuntary movement in an African schizophrenia population. Journal of Neuropsychiatry and Clinical Neurosciences 2008;20:317-26.
Overall 1962
Owens 1982
  • Owens DG, Johnstone EC, Frith CD. Spontaneous involuntary disorders of movement: their prevalence, severity,and distribution in chronic schizophrenics with and without treatment with neuroleptics. Archives of General Psychiatry 1982;39:452-61.
Sachdev 1989
Schaumburg 1983
Schünemann 2008
  • Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
Smith 1980
Soares-Weiser 2004
Tammenmaa 2002
  • Tammenmaa I, McGrath J, Sailas EES, Soares-Weiser K. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD000207]
Tenback 2007
  • Tenback DE, van Harten PN, Slooff CJ, van Os J, SOHO Study Group. Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study. Comprehensive Psychiatry 2007;48(5):436-40.
Ukoumunne 1999
  • Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):3-92.
Waddington 1987
  • Waddington JL, Youssef HA, Dolphin C, Kinsella A. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality. Archives of General Psychiatry 1987;44(10):907-12.
Woerner 1993
Xia 2009
  • Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
Yassa 1992